Skip to main content

Table 1 Prostate cancer treatment distribution for localized poorly differentiated and locally advanced PCa cases diagnosed between 2005 and 2015 by treatment status (n = 5, 361)

From: Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data

Variables

Levels

Total number of cases

Received RT only (n, %)

Received HT only (n, %)

Received both treatments (n, %)

Received none of the treatments (n, %)

Age at diagnosis, median (IQR)

73 (69–76)

73 (68–75)

74 (70–77)

73 (69–76)

73 (68–76)

Stage

Poorly differentiated

3, 546

804 (22.7)

1042 (29.4)

974 (27.4)

726 (20.5)

Locally advanced

1, 815

238 (13.1)

741 (40.8)

507 (27.9)

329 (18.1)

Tumor grade a

Low

461

59 (12.8)

196 (42.5)

129 (28.0)

77 (16.7)

High

4, 683

950 (20.3)

1500 (32.0)

1315 (28.1)

918 (19.6)

German index of socio-economic deprivation (GISD)b

Wealthiest

47

8 (17.0)

13 (27.7)

20 (42.5)

6 (12.8)

Wealthy

275

55 (20.0)

98 (35.6)

82 (29.8)

40 (14.5)

Medium

306

114 (37.2)

52 (17.0)

123 (40.2)

17 (5.6)

Poor

1, 739

277 (15.9)

662 (38.1)

455 (26.2)

345 (19.8)

Poorest

2, 566

502 (19.6)

662 (32.9)

713 (27.8)

513 (20.0)

S3-Guideline era

Pre-guideline era

1, 834

320 (17.4)

838 (32.6)

532 (29.0)

284 (15.5)

Guideline era

3, 527

722 (20.5)

1085 (30.7)

949 (26.9)

771 (21.8)

German federal states

Schleswig-Holstein

701

261 (37.2)

82 (11.7)

335 (47.8)

23 (3.3)

Brandenburg

1, 393

239 (17.2)

536 (38.5)

412 (29.6)

206 (14.8)

Mecklenburg-Vorpommern

726

137 (18.9)

192 (26.4)

210 (28.9)

187 (25.8)

Saxony

1, 913

173 (9.0)

860 (45.0)

378 (19.8)

502 (26.2)

Thuringia

628

232 (36.9)

113 (18.0)

146 (23.3)

137 (21.8)

Total

 

5, 361

1042 (19.4)

1783 (33.3)

1481 (27.6)

1055 (19.7)

  1. IQR Interquartile range, % Row percentage, a grading information was missed for about 4.05% (217) of the 5, 361 cases, b GISD information was available for 4, 933 observations, RT Radiotherapy, HT Hormonal therapy